# Avacta Group appoints BBI Solutions as manufacturing partner for the rapid SARS-CoV-2 antigen test

- Link: https://www.directorstalkinterviews.com/avacta-group-appoints-bbi-solutions-as-manufacturing-partner-for-the-rapid-sars-cov-2-antigen-test/412848943
- Published: 2020-08-06T07:09:42+01:00
- Author: Giles Arbor

**[Avacta](https://www.directorstalkinterviews.com/company/avacta-group-plc/avct.l)
Group plc** ([LON:AVCT](https://www.directorstalkinterviews.com/ftse-company/avacta-group-plc/avct.l)),
the developer of Affimer^(®) biotherapeutics and reagents, has announced that it
has appointed BBI Solutions, part of BBI Group, to manufacture the saliva-based 
rapid SARS-CoV-2 antigen test that is being developed with Cytiva.

BBI Solutions is a leading global developer and manufacturer of raw materials and
finished test products for the in-vitro diagnostics market, with manufacturing sites
in five different countries, spanning four continents**.**

The manufacturing agreement between Avacta and BBI comprises the accelerated development
and validation of a scaled-up manufacturing process that has the potential to ramp
up to a production capacity of millions of tests per month. Avacta, Cytiva and BBI
are in the process of the technology transfer of the prototype and related manufacturing
procedures for the saliva-based rapid SARS-CoV-2 antigen test from Cytiva to BBI.

Avacta aims to begin clinical validation of the test as soon as possible by using
the first pilot batches generated as part of the technology transfer process for
these studies. In parallel with these clinical validation studies, which will be
run within the UK government’s CONDOR programme and potentially with other collaborators
globally, BBI will work with Avacta and Cytiva to produce the additional technical
documentation that is required for CE marking of the final product.

> **Dr. Alastair Smith, Chief Executive of Avacta Group commented:**
> “I am delighted to be working with BBI to manufacture the rapid COVID-19 test.
> BBI has been excellent to work with to define a highly compressed product development
> timeline that will allow us to get the product to market as quickly as possible.
> We anticipate very high demand for the COVID-19 rapid test and will be working
> with our preferred manufacturing partners at BBI to satisfy that demand. We are
> actively continuing our discussions with other manufacturing partners to ensure
> that we have access to additional manufacturing capacity to address the global
> need for SARS-CoV-2 antigen testing both now, and in the next few years.
> As we set out in the use of proceeds at the recent fund raising, we have now expanded
> our product development team with the appointment of an experienced in-vitro diagnostic
> Product Development Manager, and we are expanding the protein production facilities
> in order to meet the expected demand for Affimer proteins for the COVID-19 tests
> and future diagnostic tests in the pipeline. 
> The diagnostics business has also been working at a rapid pace towards ISO13485
> accreditation, which will streamline CE marking and other regulatory approval 
> processes.
> I am immensely proud of what has been achieved by Avacta’s diagnostics team. Their
> progress in just a few months would have been challenging under normal circumstances,
> but with the additional restrictions imposed by COVID-19, it has been an outstanding
> example of hard work, ingenuity and commitment from a world-class team.
> I look forward to further updating the market as we go through the next stages
> of manufacturing scale-up, clinical validation, regulatory approval and product
> launch.”

> **Dr. Mario Gualano, Chief Executive of BBI Group:**
> “BBI are delighted to have been appointed to lead the manufacture of Avacta’s 
> rapid coronavirus antigen test, and to be able to further extend our lateral flow
> expertise to addressing the global challenges presented by COVID-19.
> Our ability to respond rapidly to Avacta’s needs is testament to our team’s diagnostic
> expertise and the supporting manufacturing and quality systems we have implemented
> at our ISO13485 accredited facility.”

[You can listen to a full interview with Alastair Smith discussing this news here.](https://www.directorstalkinterviews.com/avacta-group-transfer-technology-to-bbi-solutions-for-manufacture-of-covid-19-test-interview/412849013)

Share on:
